Priority Lists
Protocol Posting of
Activations
Activation
A Phase III Trial of CHOP vs. CHOP + Rituximab vs. CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) For Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas
| Study Coordinator(s) | Oliver W. Press, M.D.,Ph.D., David G. Maloney, M.D.,Ph.D., Rita M. Braziel, M.D. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists, Radiation Oncologists, Pathologists, CALGB, CTSU |
Closures
Amendments, Revisions, Memoranda
Amendment #1
A Phase II Study of 506U78 in Patients with Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
| Study Coordinator(s) | Steven E. Coutre, M.D., Alison T. Stopeck, M.D. |
| Participants | Pathologists, NCORP, Members |
Revision #5 regarding NCCTG Addendum #10
A Randomized Phase III Trial of Combinations of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU) and Irinotecan (CPT-11) as Initial Treatment of Patients With Advanced Adenocarcinoma of the Colon and Rectum
| Study Coordinator(s) | Stephen K. Williamson, M.D. |
| Participants | Members, Surgeons, NCORP |
Revision #4 regarding NCCTG Addendum #5.
A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients with Advanced Colorectal Carcinoma Previously Treated with 5-FU
| Study Coordinator(s) | Philip A. Philip, M.D.,Ph.D. |
| Participants | Members, Surgeons, NCORP |
Activation Notice
Phase III Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin and Radiotherapy in Carcinoma of the Anal Canal
| Study Coordinator(s) | Charles R. Thomas Jr., M.D., Kevin G. Billingsley, M.D. |
| Participants | NCORP, Members, Surgeons, Radiation Oncologists |
Amendment #1
A Phase II Trial of 506U78 (IND 52611) in Patients With Relapsed or Refractory Non T-Cell Acute Lymphoblastic Leukemia (ALL)
| Study Coordinator(s) | Steven E. Coutre, M.D., David R. Head, M.D., David H. Boldt, M.D., Marilyn L. Slovak, Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
Revision #10
Phase III Randomized Trial of 12 Months VS 3 Months of Paclitaxel in Patients with Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy (Intergroup)
| Study Coordinator(s) | Maurie Markman, M.D., Bradley J. Monk, M.D., Sharon Wilczynski, M.D.,Ph.D. |
| Participants | Members, Pathologists, Surgeons, GOG, NCORP |
Revision #2
Repository for Paraffin Embedded Tissues from Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).
| Study Coordinator(s) | Wolfram E. Samlowski, M.D., Heinz- Josef Lenz, M.D., Joseph A. Holden, M.D., Kurt H. Albertine, Ph.D. |
| Participants | Members, Medical Oncologists, Pathologists, NCORP |
Revision #2
A Phase III Randomized Study Comparing Busulfan – Total Body Irradiation Versus Cyclophosphamide – Total Body Irradiation Preparative Regimen in Patients with Advanced Myelodysplastic Syndrome (MDS) or MDS – Related Acute Myeloid Leukemia (AML) Undergoing HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation, (A BMT Study)
| Study Coordinator(s) | Jeanne E. Anderson, M.D., Karl G. Blume, M.D., Margaret R. O'Donnell, M.D., David R. Head, M.D., Cheryl L. Willman, M.D., Marilyn L. Slovak, Ph.D. |
| Participants | Limited Institutions: SWOG Approved Autologous BMT Facilities |
Amendment #1
A Phase III Trial of Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin (DCEP) and G-CSF With or Without Thalidomide (NSC #66847) as Salvage Therapy for Patients with Refractory Multiple Myeloma
| Study Coordinator(s) | Mohamad A. Hussein, M.D., James K. Weick, M.D. |
| Participants | NCORP, Members |
Memorandum concerning adverse events
A Phase II Trial of R115777 (NSC #70818) in Patients with Advanced Colorectal Cancer.
| Study Coordinator(s) | Robert P. Whitehead, M.D., John S. Macdonald, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Memorandum regarding adverse events
A Phase II Trial of R115777 (NSC #70818) in Patients with Advanced Pancreas Cancer.
| Study Coordinator(s) | John S. Macdonald, M.D., Robert P. Whitehead, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Amendment #3
A Study of the Late Cardiac Effects of Two Different Adjuvant Chemotherapy Regimens in Women With Node Negative Breast Cancer Treated on SWOG-8897
| Study Coordinator(s) | Patricia A. Ganz, M.D., Laura F. Hutchins, M.D. |
| Participants | Members, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists, NCORP |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required